Theriva Biologics Reports Net Loss of $10.25 Million for the First Half of 2023
Company's Revenue Stands at $5.82 Million Amidst Challenging Market Conditions
Theriva Biologics, Inc.(SYN) and its subsidiaries have r eleased their consolidated financial results for the first half of 2023, revealing a net loss of $10.25 million. The company also reported revenue totaling $5.82 million during this period. The biotechnology firm, operating in a competitive market landscape, experienced fluctuations in both its net income/loss and revenue figures. Here is a comprehensive breakdown of their financial performance and key highlights from the recent reporting period
Current Assets Show Decline
The company's current assets, including cash and cash equivalents along with prepaid expenses, witnessed a decrease from $45.52 million at the end of 2022 to $37.96 million as of June 30, 2023. Cash and cash equivalents specifically decreased from $41.79 million to $34.25 million over the same period.
Non-Current Assets and Liabilities
